Sozinibercept (Research-Grade) is a research-grade biosimilar monoclonal antibody. Reactivity: Human. Supplied as a liquid in 0.01M PBS pH 7.4. Applications: ELISA, functional assays and in vivo research. Endotoxin: < 10 EU/mg. Purity: >95% purity as determined by SDS-PAGE. For research use only.
Sozinibercept (OPT 302; VGX-300) is a soluble form of VEGFR-3, potently inhibits the activity of VEGF-C/D, which are the proangiogenic factors, inhibiting angiogenesis and vascular leakage. Sozinibercept also inhibits diabetic retinal edema in rats.
Product Name:
Sozinibercept (Research-Grade)
SKU:
GXBS02282
Size:
100 µg, 1 mg
Antibody Type:
Monoclonal Antibody
Target:
Vascular endothelial growth factor C
Isotype:
Vascular Endothelial Growth Factor Receptor 3 fusion protein with IgG1 Fc Fragment.
Reactivity:
Human
Applications:
ELISA, Functional assay, Research in vivo
Expression Host:
Mammalian cells
Synonyms:
OPT-302, solubleVEGFR-3, sozinibercept, VGX-300
Biological Activity:
Sozinibercept inhibits CNV lesion formation and vascular leakage in the mouse laser-induced model of choroidal neovascularization (CNV). Moreover, Sozinibercept exhibits comparable efficacy to Aflibercept (; Eylea ®) in CNV mouse model [1] [2]. Sozinibercept (intravitreal injection; once every 4 wk for 4 months) shows selective inhibition of VEGF-C/D, and inhibits diabetic retinal edema induced by streptozotocin (STZ) in the rat model, and equivalent to inhibition of VEGF-A inhibitor (Aflibercept) [3].
Purity:
>95% purity as determined by SDS-PAGE.
Endotoxin Level:
< 10 EU/mg
Formulation:
0.01M PBS pH 7.4
State of Matter:
Liquid
Regulatory Status:
For research use only. Not suitable for clinical or therapeutic use.
Product Preparation:
Protein A/G purified from cell culture supernatant.
Storage and Handling:
Store at 2 to 8°C for frequent use. Store at -20 to -80°C for twelve months from the date of receipt.
